The approval of Fyarro, an mTOR inhibitor, was based on data from the phase 2 AMPECT study, which included 34 adults with advanced malignant PEComa. The Food and Drug Administration (FDA) has approved ...
--Aadi Bioscience, Inc., a biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that the U.S. Food and Drug ...
Vascular tumors of the liver in adult patients include cavernous hemangioma, a common benign tumor; epithelioid hemangioendothelioma, a rare, usually low-grade malignant tumor; and angiosarcoma, a ...
As a passionate dancer, Cristina enjoyed an active life of dancing jazz, musical theater, Latin and belly dancing for many years. However, after a routine visit to her doctor in 2013, Cristina’s world ...
The aim of our study was to investigate whether H3K27 tri-methylation is useful as a diagnostic and/or prognostic marker for malignant peripheral nerve sheath tumors. H3K27 immunohistochemistry was ...
Fyarro has also been added to the NCCN Guidelines as the only preferred treatment regimen for malignant PEComa. Fyarro (sirolimus protein-bound particles [albumin-bound]) has been made available for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results